The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2016 | The management of transaminitis in patients receiving idelalisib
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX gives an overview of his poster on the ‘Management of transaminase elevations in patients receiving idelalisib’ in chronic lymphocytic leukemia (CLL) presented at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. According to Dr Wierda, transaminitis can be seen in patients who are initiating on idelalisib after approximately 2-4 weeks and is usually reversible. The management of this side effect is important in order to avoid damage to the liver.
